Related references
Note: Only part of the references are listed.1245PA PHASE 3 RANDOMISED TRIAL OF ADDING NITROGLYCERIN TO FIRST LINE CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER: THE AUSTRALASIAN LUNG CANCER TRIALS GROUP NITRO TRIAL
A. Davidson et al.
ANNALS OF ONCOLOGY (2017)
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
Rebecca S. Heist et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
N. Reinmuth et al.
LUNG CANCER (2014)
Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer
Joachim G. Aerts et al.
CANCER RESEARCH (2013)
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
Annamaria Rapisarda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Solid tumor physiology and hypoxia-induced chemo/radio-resistance: Novel strategy for cancer therapy: Nitric oxide donor as a therapeutic enhancer
Hiroyasu Yasuda
NITRIC OXIDE-BIOLOGY AND CHEMISTRY (2008)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma
Hiroyasu Yasuda et al.
CLINICAL CANCER RESEARCH (2006)
VEGF receptor signalling - in control of vascular function
AK Olsson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer
H Yasuda et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Hypoxic inducible factor 1α, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide
DD Thomas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Clinical translation of angiogenesis inhibitors
R Kerbel et al.
NATURE REVIEWS CANCER (2002)
Changes in tumor oxygenation/perfusion induced by the NO donor, isosorbide dinitrate, in comparison with carbogen: Monitoring by EPR and MRI
BF Jordan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
Share Paper
